Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.
Location: United States, New York
Employees: 11-50
Total raised: $10M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.11.2020 | - | $10M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 30.08.2022 | Arch builds bridge to new class of medicines, leading $50M i... | Arch Venture Partners is bankrolling a biotech that could render high-throughput screening obsolete.... | fiercebiot... |
| 13.11.2020 | Bridge Medicines Raises $10M in Additional Funding | Bridge Medicines, a NYC-based drug discovery company focused on advancing promising early technologi... | finsmes.co... |
| 14.01.2020 | Innovation in biotech R&D: New resources offer new hope | Public optimism about American health care seems in short supply if you read the news, which is domi... | statnews.c... |